Vaccination against tuberculosis: How can we better BCG?

Microbial Pathogenesis

Volumn 58, Issue , 2013, Pages 2-16

  Pitt, Jonathan M ^a   Blankley, Simon ^a   McShane, Helen ^b   O'Garra, Anne ^a  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

BCG; Immunomodulation; Prime boost; T helper cell; Tuberculosis

Indexed keywords

ADAG 85 A; AERAS 402; AERAS 404; AERAS 422; AERAS 485; ALPHA BETA INTERFERON RECEPTOR; BACTERIAL VACCINE; BCG VACCINE; CULTURE FILTRATE PROTEIN 10; DNA VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; HYBRID 1; HYVAC4; ID 93; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P35; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 23; M 72; MVA 85 A; MYCOBACTERIUM INDICUS PRANII WHOLE CELL VACCINE; MYCOBACTERIUM VACCAE WHOLE CELL VACCINE; RECOMBINANT BCG30 VACCINE; RECOMBINANT VACCINE; SRL 172; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VPM 1002;

ANTIGEN RECOGNITION; ARTICLE; BCG VACCINATION; CELLULAR IMMUNITY; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GRANULOMA; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFECTION PREVENTION; INNATE IMMUNITY; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROVOCATION TEST; TH1 CELL; TH17 CELL; TUBERCULOUS GRANULOMA; UNSPECIFIED SIDE EFFECT;

BCG VACCINE; DRUG DISCOVERY; HUMANS; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY; VACCINATION;

MYCOBACTERIUM TUBERCULOSIS;

EID: 84875868248     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2012.12.002     Document Type: Article

References (244)

1. North R.J., Jung Y.J. Immunity to tuberculosis. Annu Rev Immunol 2004, 22:599-623.
2. Koch R. Die aetiologie der tuberculose. Berliner Klinische Wochenschrift 1882, 19:221-230.
3. W.H.O Global tuberculosis control 2011, World Health Organisation.
4. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104.
5. Nunn P., Williams B., Floyd K., Dye C., Elzinga G., Raviglione M. Tuberculosis control in the era of HIV. Nat Rev Immunol 2005, 5:819-826.
6. Lawn S.D., Zumla A.I. Tuberculosis. Lancet 2011, 378:57-72.
7. Nathan C. Taming tuberculosis: a challenge for science and society. Cell Host Microbe 2009, 5:220-224.
8. Fine P.E. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995, 346:1339-1345.
9. Trunz B.B., Fine P., Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006, 367:1173-1180.
10. Raviglione M.C., Uplekar M.W. WHO's new stop TB strategy. Lancet 2006, 367:952-955.
11. Young D.B., Perkins M.D., Duncan K., Barry C.E. Confronting the scientific obstacles to global control of tuberculosis. J Clin Invest 2008, 118:1255-1265.
12. Jouanguy E., Altare F., Lamhamedi S., Revy P., Emile J.F., Newport M., et al. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N Engl J Med 1996, 335:1956-1961.
13. W.H.O Revised BCG vaccination guidelines for infants at risk for HIV infection. Wkly Epidemiol Rec 2007, 82:193-196.
14. Dye C., Scheele S., Dolin P., Pathania V., Raviglione M.C. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO global surveillance and monitoring project. JAMA 1999, 282:677-686.
15. Young D.B., Gideon H.P., Wilkinson R.J. Eliminating latent tuberculosis. Trends Microbiol 2009, 17:183-188.
16. Barry C.E., Boshoff H.I., Dartois V., Dick T., Ehrt S., Flynn J., et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009, 7:845-855.
17. Sturgill-Koszycki S., Schlesinger P.H., Chakraborty P., Haddix P.L., Collins H.L., Fok A.K., et al. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 1994, 263:678-681.
18. Armstrong J.A., Hart P.D. Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes. J Exp Med 1971, 134:713-740.
19. Egen J.G., Rothfuchs A.G., Feng C.G., Winter N., Sher A., Germain R.N. Macrophage and T cell dynamics during the development and disintegration of mycobacterial granulomas. Immunity 2008, 28:271-284.
20. Flynn J.L., Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001, 19:93-129.
21. Lowe D.M., Redford P.S., Wilkinson R.J., O'Garra A., Martineau A.R. Neutrophils in tuberculosis: friend or foe?. Trends Immunol 2011, 33:14-25.
22. Blomgran R., Ernst J.D. Lung neutrophils facilitate activation of naive antigen-specific CD4+ T cells during Mycobacterium tuberculosis infection. J Immunol 2011, 186:7110-7119.
23. Eum S.Y., Kong J.H., Hong M.S., Lee Y.J., Kim J.H., Hwang S.H., et al. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 2010, 137:122-128.
24. Eruslanov E.B., Lyadova I.V., Kondratieva T.K., Majorov K.B., Scheglov I.V., Orlova M.O., et al. Neutrophil responses to Mycobacterium tuberculosis infection in genetically susceptible and resistant mice. Infect Immun 2005, 73:1744-1753.
25. Keller C., Hoffmann R., Lang R., Brandau S., Hermann C., Ehlers S. Genetically determined susceptibility to tuberculosis in mice causally involves accelerated and enhanced recruitment of granulocytes. Infect Immun 2006, 74:4295-4309.
26. Steinman R.M., Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 2006, 311:17-58.
27. Steinman R.M. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 2012, 30:1-22.
28. Wolf A.J., Linas B., Trevejo-Nunez G.J., Kincaid E., Tamura T., Takatsu K., et al. Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo. J Immunol 2007, 179:2509-2519.
29. Humphreys I.R., Stewart G.R., Turner D.J., Patel J., Karamanou D., Snelgrove R.J., et al. A role for dendritic cells in the dissemination of mycobacterial infection. Microbe Infect 2006, 8:1339-1346.
30. Cooper A.M. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009, 27:393-422.
31. Mogues T., Goodrich M.E., Ryan L., LaCourse R., North R.J. The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. J Exp Med 2001, 193:271-280.
32. Orme I.M. The kinetics of emergence and loss of mediator T lymphocytes acquired in response to infection with Mycobacterium tuberculosis. J Immunol 1987, 138:293-298.
33. Scanga C.A., Mohan V.P., Yu K., Joseph H., Tanaka K., Chan J., et al. Depletion of CD4 (+) T cells causes reactivation of murine persistent tuberculosis despite continued expression of interferon gamma and nitric oxide synthase 2. J Exp Med 2000, 192:347-358.
34. Diedrich C.R., Flynn J.L. HIV-1/mycobacterium tuberculosis coinfection immunology: how does HIV-1 exacerbate tuberculosis?. Infect Immun 2011, 79:1407-1417.
35. Ulrichs T., Kosmiadi G.A., Trusov V., Jorg S., Pradl L., Titukhina M., et al. Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung. J Pathol 2004, 204:217-228.
36. Gallegos A.M., van Heijst J.W., Samstein M., Su X., Pamer E.G., Glickman M.S. A gamma interferon independent mechanism of CD4 T cell mediated control of M. tuberculosis infection in vivo. PLoS Pathog 2011, 7:e1002052.
37. Dalton D.K., Pitts-Meek S., Keshav S., Figari I.S., Bradley A., Stewart T.A. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 1993, 259:1739-1742.
38. Russell D.G., VanderVen B.C., Lee W., Abramovitch R.B., Kim M.J., Homolka S., et al. Mycobacterium tuberculosis wears what it eats. Cell Host Microbe 2010, 8:68-76.
39. Gonzalez-Juarrero M., Turner O.C., Turner J., Marietta P., Brooks J.V., Orme I.M. Temporal and spatial arrangement of lymphocytes within lung granulomas induced by aerosol infection with Mycobacterium tuberculosis. Infect Immun 2001, 69:1722-1728.
40. Russell D.G., Cardona P.J., Kim M.J., Allain S., Altare F. Foamy macrophages and the progression of the human tuberculosis granuloma. Nat Immunol 2009, 10:943-948.
41. Ramakrishnan L. Revisiting the role of the granuloma in tuberculosis. Nat Rev Immunol 2012, 12:352-366.
42. Lin P.L., Rodgers M., Smith L., Bigbee M., Myers A., Bigbee C., et al. Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect Immun 2009, 77:4631-4642.
43. Brightbill H.D., Libraty D.H., Krutzik S.R., Yang R.B., Belisle J.T., Bleharski J.R., et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 1999, 285:732-736.
44. Means T.K., Wang S., Lien E., Yoshimura A., Golenbock D.T., Fenton M.J. Human toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. J Immunol 1999, 163:3920-3927.
45. Berrington W.R., Hawn T.R. Mycobacterium tuberculosis, macrophages, and the innate immune response: does common variation matter?. Immunol Rev 2007, 219:167-186.
46. Bafica A., Scanga C.A., Feng C.G., Leifer C., Cheever A., Sher A. TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J Exp Med 2005, 202:1715-1724.
47. Bulut Y., Michelsen K.S., Hayrapetian L., Naiki Y., Spallek R., Singh M., et al. Mycobacterium tuberculosis heat shock proteins use diverse Toll-like receptor pathways to activate pro-inflammatory signals. J Biol Chem 2005, 280:20961-20967.
48. Kleinnijenhuis J., Oosting M., Joosten L.A., Netea M.G., Van Crevel R. Innate immune recognition of Mycobacterium tuberculosis. Clin Dev Immunol 2011, 2011:405310.
49. Geijtenbeek T.B., Van Vliet S.J., Koppel E.A., Sanchez-Hernandez M., Vandenbroucke-Grauls C.M., Appelmelk B., et al. Mycobacteria target DC-SIGN to suppress dendritic cell function. J Exp Med 2003, 197:7-17.
50. Gringhuis S.I., den Dunnen J., Litjens M., van der Vlist M., Geijtenbeek T.B. Carbohydrate-specific signaling through the DC-SIGN signalosome tailors immunity to Mycobacterium tuberculosis, HIV-1 and Helicobacter pylori. Nat Immunol 2009, 10:1081-1088.
51. Yadav M., Schorey J.S. The beta-glucan receptor dectin-1 functions together with TLR2 to mediate macrophage activation by mycobacteria. Blood 2006, 108:3168-3175.
52. Schoenen H., Bodendorfer B., Hitchens K., Manzanero S., Werninghaus K., Nimmerjahn F., et al. cutting edge: mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J Immunol 2010, 184:2756-2760.
53. Werninghaus K., Babiak A., Gross O., Holscher C., Dietrich H., Agger E.M., et al. Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation. J Exp Med 2009, 206:89-97.
54. Ishikawa E., Ishikawa T., Morita Y.S., Toyonaga K., Yamada H., Takeuchi O., et al. Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. J Exp Med 2009, 206:2879-2888.
55. Mankia S., Peters J.E., Kang S., Moore S., Ehrenstein M.R. Tuberculosis and anti-TNF treatment: experience of a central London hospital. Clin Rheumatol 2011, 30:399-401.
56. Bean A.G., Roach D.R., Briscoe H., France M.P., Korner H., Sedgwick J.D., et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 1999, 162:3504-3511.
57. Flynn J.L., Goldstein M.M., Chan J., Triebold K.J., Pfeffer K., Lowenstein C.J., et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995, 2:561-572.
58. Algood H.M., Lin P.L., Yankura D., Jones A., Chan J., Flynn J.L. TNF influences chemokine expression of macrophages in vitro and that of CD11b+ cells in vivo during Mycobacterium tuberculosis infection. J Immunol 2004, 172:6846-6857.
59. Chakravarty S.D., Zhu G., Tsai M.C., Mohan V.P., Marino S., Kirschner D.E., et al. Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs. Infect Immun 2008, 76:916-926.
60. Mohan V.P., Scanga C.A., Yu K., Scott H.M., Tanaka K.E., Tsang E., et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 2001, 69:1847-1855.
61. Lin P.L., Myers A., Smith L., Bigbee C., Bigbee M., Fuhrman C., et al. Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. Arthritis Rheum 2010, 62:340-350.
62. Fremond C.M., Togbe D., Doz E., Rose S., Vasseur V., Maillet I., et al. IL-1 receptor-mediated signal is an essential component of MyD88-dependent innate response to Mycobacterium tuberculosis infection. J Immunol 2007, 179:1178-1189.
63. Mayer-Barber K.D., Barber D.L., Shenderov K., White S.D., Wilson M.S., Cheever A., et al. Caspase-1 independent IL-1beta production is critical for host resistance to mycobacterium tuberculosis and does not require TLR signaling in vivo. J Immunol 2010, 184:3326-3330.
64. Mayer-Barber K.D., Andrade B.B., Barber D.L., Hieny S., Feng C.G., Caspar P., et al. Innate and adaptive interferons suppress IL-1alpha and IL-1beta production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity 2011, 35:1023-1034.
65. Alcais A., Fieschi C., Abel L., Casanova J.L. Tuberculosis in children and adults: two distinct genetic diseases. J Exp Med 2005, 202:1617-1621.
66. Casanova J.L., Abel L. Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol 2002, 20:581-620.
67. Hsieh C.S., Macatonia S.E., Tripp C.S., Wolf S.F., O'Garra A., Murphy K.M. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993, 260:547-549.
68. Macatonia S.E., Hosken N.A., Litton M., Vieira P., Hsieh C.S., Culpepper J.A., et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol 1995, 154:5071-5079.
69. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003, 3:133-146.
70. O'Garra A., Murphy K.M. From IL-10 to IL-12: how pathogens and their products stimulate APCs to induce T(H)1 development. Nat Immunol 2009, 10:929-932.
71. O'Garra A., Hosken N., Macatonia S., Wenner C.A., Murphy K. The role of macrophage- and dendritic cell-derived IL12 in Th1 phenotype development. Res Immunol 1995, 146:466-472.
72. Neighbors M., Xu X., Barrat F.J., Ruuls S.R., Churakova T., Debets R., et al. A critical role for interleukin 18 in primary and memory effector responses to Listeria monocytogenes that extends beyond its effects on Interferon gamma production. J Exp Med 2001, 194:343-354.
73. Remus N., El Baghdadi J., Fieschi C., Feinberg J., Quintin T., Chentoufi M., et al. Association of IL12RB1 polymorphisms with pulmonary tuberculosis in adults in Morocco. J Infect Dis 2004, 190:580-587.
74. Ottenhoff T.H., Kumararatne D., Casanova J.L. Novel human immunodeficiencies reveal the essential role of type-I cytokines in immunity to intracellular bacteria. Immunol Today 1998, 19:491-494.
75. Dawson R., Condos R., Tse D., Huie M.L., Ress S., Tseng C.H., et al. Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis. PLoS One 2009, 4:e6984.
76. Reljic R. IFN-gamma therapy of tuberculosis and related infections. J Interferon Cytokine Res 2007, 27:353-364.
77. Cooper A.M., Magram J., Ferrante J., Orme I.M. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with mycobacterium tuberculosis. J Exp Med 1997, 186:39-45.
78. Cooper A.M., Roberts A.D., Rhoades E.R., Callahan J.E., Getzy D.M., Orme I.M. The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection. Immunology 1995, 84:423-432.
79. Flynn J.L., Goldstein M.M., Triebold K.J., Sypek J., Wolf S., Bloom B.R. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J Immunol 1995, 155:2515-2524.
80. Cooper A.M., Kipnis A., Turner J., Magram J., Ferrante J., Orme I.M. Mice lacking bioactive IL-12 can generate protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present. J Immunol 2002, 168:1322-1327.
81. Holscher C., Atkinson R.A., Arendse B., Brown N., Myburgh E., Alber G., et al. A protective and agonistic function of IL-12p40 in mycobacterial infection. J Immunol 2001, 167:6957-6966.
82. Khader S.A., Partida-Sanchez S., Bell G., Jelley-Gibbs D.M., Swain S., Pearl J.E., et al. Interleukin 12p40 is required for dendritic cell migration and T cell priming after Mycobacterium tuberculosis infection. J Exp Med 2006, 203:1805-1815.
83. Schaible U.E., Sturgill-Koszycki S., Schlesinger P.H., Russell D.G. Cytokine activation leads to acidification and increases maturation of Mycobacterium avium-containing phagosomes in murine macrophages. J Immunol 1998, 160:1290-1296.
84. Cooper A.M., Dalton D.K., Stewart T.A., Griffin J.P., Russell D.G., Orme I.M. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993, 178:2243-2247.
85. Flynn J.L., Chan J., Triebold K.J., Dalton D.K., Stewart T.A., Bloom B.R. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993, 178:2249-2254.
86. Kamijo R., Le J., Shapiro D., Havell E.A., Huang S., Aguet M., et al. Mice that lack the interferon-gamma receptor have profoundly altered responses to infection with Bacillus Calmette-Guerin and subsequent challenge with lipopolysaccharide. J Exp Med 1993, 178:1435-1440.
87. MacMicking J.D., North R.J., LaCourse R., Mudgett J.S., Shah S.K., Nathan C.F. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci U S A 1997, 94:5243-5248.
88. Scanga C.A., Mohan V.P., Tanaka K., Alland D., Flynn J.L., Chan J. The inducible nitric oxide synthase locus confers protection against aerogenic challenge of both clinical and laboratory strains of Mycobacterium tuberculosis in mice. Infect Immun 2001, 69:7711-7717.
89. Cooper A.M., Segal B.H., Frank A.A., Holland S.M., Orme I.M. Transient loss of resistance to pulmonary tuberculosis in p47(phox-/-) mice. Infect Immun 2000, 68:1231-1234.
90. Khader S.A., Cooper A.M. IL-23 and IL-17 in tuberculosis. Cytokine 2008, 41:79-83.
91. Miossec P., Korn T., Kuchroo V.K. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009, 361:888-898.
92. Cooper A.M., Solache A., Khader S.A. Interleukin-12 and tuberculosis: an old story revisited. Curr Opin Immunol 2007, 19:441-447.
93. Khader S.A., Pearl J.E., Sakamoto K., Gilmartin L., Bell G.K., Jelley-Gibbs D.M., et al. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J Immunol 2005, 175:788-795.
94. Wozniak T.M., Ryan A.A., Britton W.J. Interleukin-23 restores immunity to Mycobacterium tuberculosis infection in IL-12p40-deficient mice and is not required for the development of IL-17-secreting T cell responses. J Immunol 2006, 177:8684-8692.
95. Aujla S.J., Chan Y.R., Zheng M., Fei M., Askew D.J., Pociask D.A., et al. IL-22 mediates mucosal host defense against gram-negative bacterial pneumonia. Nat Med 2008, 14:275-281.
96. Aujla S.J., Dubin P.J., Kolls J.K. Th17 cells and mucosal host defense. Semin Immunol 2007, 19:377-382.
97. Khader S.A., Guglani L., Rangel-Moreno J., Gopal R., Junecko B.A., Fountain J.J., et al. IL-23 is required for long-term control of Mycobacterium tuberculosis and B cell follicle formation in the infected lung. J Immunol 2011, 187:5402-5407.
98. Umemura M., Yahagi A., Hamada S., Begum M.D., Watanabe H., Kawakami K., et al. IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. J Immunol 2007, 178:3786-3796.
99. Okamoto Yoshida Y., Umemura M., Yahagi A., O'Brien R.L., Ikuta K., Kishihara K., et al. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol 2010, 184:4414-4422.
100. Lockhart E., Green A.M., Flynn J.L. IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J Immunol 2006, 177:4662-4669.
101. Khader S.A., Bell G.K., Pearl J.E., Fountain J.J., Rangel-Moreno J., Cilley G.E., et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007, 8:369-377.
102. Gopal R., Lin Y., Obermajer N., Slight S., Nuthalapati N., Ahmed M., et al. IL-23-dependent IL-17 drives Th1-cell responses following Mycobacterium bovis BCG vaccination. Eur J Immunol 2012, 42:364-373.
103. Vordermeier H.M., Villarreal-Ramos B., Cockle P.J., McAulay M., Rhodes S.G., Thacker T., et al. Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect Immun 2009, 77:3364-3373.
104. Turner J., Rhoades E.R., Keen M., Belisle J.T., Frank A.A., Orme I.M. Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. Infect Immun 2000, 68:1706-1709.
105. Cruz A., Fraga A.G., Fountain J.J., Rangel-Moreno J., Torrado E., Saraiva M., et al. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J Exp Med 2010, 207:1609-1616.
106. Moore K.W., de Waal Malefyt R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765.
107. O'Garra A., Vieira P. T(H)1 cells control themselves by producing interleukin-10. Nat Rev Immunol 2007, 7:425-428.
108. Gazzinelli R.T., Wysocka M., Hieny S., Scharton-Kersten T., Cheever A., Kuhn R., et al. In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. J Immunol 1996, 157:798-805.
109. Hunter C.A., Ellis-Neyes L.A., Slifer T., Kanaly S., Grunig G., Fort M., et al. IL-10 is required to prevent immune hyperactivity during infection with Trypanosoma cruzi. J Immunol 1997, 158:3311-3316.
110. Li C., Corraliza I., Langhorne J. A defect in interleukin-10 leads to enhanced malarial disease in Plasmodium chabaudi chabaudi infection in mice. Infect Immun 1999, 67:4435-4442.
111. Dai W.J., Kohler G., Brombacher F. Both innate and acquired immunity to Listeria monocytogenes infection are increased in IL-10-deficient mice. J Immunol 1997, 158:2259-2267.
112. Belkaid Y., Hoffmann K.F., Mendez S., Kamhawi S., Udey M.C., Wynn T.A., et al. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 2001, 194:1497-1506.
113. Murray H.W., Lu C.M., Mauze S., Freeman S., Moreira A.L., Kaplan G., et al. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect Immun 2002, 70:6284-6293.
114. Brooks D.G., Trifilo M.J., Edelmann K.H., Teyton L., McGavern D.B., Oldstone M.B. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 2006, 12:1301-1309.
115. Ejrnaes M., Filippi C.M., Martinic M.M., Ling E.M., Togher L.M., Crotty S., et al. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med 2006, 203:2461-2472.
116. Jung Y.J., Ryan L., LaCourse R., North R.J. Increased interleukin-10 expression is not responsible for failure of T helper 1 immunity to resolve airborne Mycobacterium tuberculosis infection in mice. Immunology 2003, 109:295-299.
117. North R.J. Mice incapable of making IL-4 or IL-10 display normal resistance to infection with Mycobacterium tuberculosis. Clin Exp Immunol 1998, 113:55-58.
118. Higgins D.M., Sanchez-Campillo J., Rosas-Taraco A.G., Lee E.J., Orme I.M., Gonzalez-Juarrero M. Lack of IL-10 alters inflammatory and immune responses during pulmonary Mycobacterium tuberculosis infection. Tuberculosis (Edinb) 2009, 89:149-157.
119. Murray P.J., Young R.A. Increased antimycobacterial immunity in interleukin-10-deficient mice. Infect Immun 1999, 67:3087-3095.
120. Roach D.R., Martin E., Bean A.G., Rennick D.M., Briscoe H., Britton W.J. Endogenous inhibition of antimycobacterial immunity by IL-10 varies between mycobacterial species. Scand J Immunol 2001, 54:163-170.
121. Murray P.J., Wang L., Onufryk C., Tepper R.I., Young R.A. T cell-derived IL-10 antagonizes macrophage function in mycobacterial infection. J Immunol 1997, 158:315-321.
122. Turner J., Gonzalez-Juarrero M., Ellis D.L., Basaraba R.J., Kipnis A., Orme I.M., et al. In vivo IL-10 production reactivates chronic pulmonary tuberculosis in C57BL/6 mice. J Immunol 2002, 169:6343-6351.
123. Beamer G.L., Flaherty D.K., Assogba B.D., Stromberg P., Gonzalez-Juarrero M., de Waal Malefyt R., et al. Interleukin-10 promotes Mycobacterium tuberculosis disease progression in CBA/J mice. J Immunol 2008, 181:5545-5550.
124. Redford P.S., Boonstra A., Read S., Pitt J., Graham C., Stavropoulos E., et al. Enhanced protection to Mycobacterium tuberculosis infection in IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung. Eur J Immunol 2010, 40:2200-2210.
125. Barnes P.F., Lu S., Abrams J.S., Wang E., Yamamura M., Modlin R.L. Cytokine production at the site of disease in human tuberculosis. Infect Immun 1993, 61:3482-3489.
126. Verbon A., Juffermans N., Van Deventer S.J., Speelman P., Van Deutekom H., Van Der Poll T. Serum concentrations of cytokines in patients with active tuberculosis (TB) and after treatment. Clin Exp Immunol 1999, 115:110-113.
127. Bonecini-Almeida M.G., Ho J.L., Boechat N., Huard R.C., Chitale S., Doo H., et al. Down-modulation of lung immune responses by interleukin-10 and transforming growth factor beta (TGF-beta) and analysis of TGF-beta receptors I and II in active tuberculosis. Infect Immun 2004, 72:2628-2634.
128. Redford P.S., Murray P.J., O'Garra A. The role of IL-10 in immune regulation during M. tuberculosis infection. Mucosal Immunol 2011, 4:261-270.
129. Gong J.H., Zhang M., Modlin R.L., Linsley P.S., Iyer D., Lin Y., et al. Interleukin-10 downregulates Mycobacterium tuberculosis-induced Th1 responses and CTLA-4 expression. Infect Immun 1996, 64:913-918.
130. Gerosa F., Nisii C., Righetti S., Micciolo R., Marchesini M., Cazzadori A., et al. CD4 (+) T cell clones producing both interferon-gamma and interleukin-10 predominate in bronchoalveolar lavages of active pulmonary tuberculosis patients. Clin Immunol 1999, 92:224-234.
131. Boussiotis V.A., Tsai E.Y., Yunis E.J., Thim S., Delgado J.C., Dascher C.C., et al. IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J Clin Invest 2000, 105:1317-1325.
132. Newton S.M., Smith R.J., Wilkinson K.A., Nicol M.P., Garton N.J., Staples K.J., et al. A deletion defining a common Asian lineage of Mycobacterium tuberculosis associates with immune subversion. Proc Natl Acad Sci U S A 2006, 103:15594-15598.
133. Trinchieri G. Type I interferon: friend or foe?. J Exp Med 2010, 207:2053-2063.
134. Henry T., Kirimanjeswara G.S., Ruby T., Jones J.W., Peng K., Perret M., et al. Type I IFN signaling constrains IL-17A/F secretion by gammadelta T cells during bacterial infections. J Immunol 2010, 184:3755-3767.
135. Auerbuch V., Brockstedt D.G., Meyer-Morse N., O'Riordan M., Portnoy D.A. Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes. J Exp Med 2004, 200:527-533.
136. Carrero J.A., Calderon B., Unanue E.R. Type I interferon sensitizes lymphocytes to apoptosis and reduces resistance to Listeria infection. J Exp Med 2004, 200:535-540.
137. Manca C., Tsenova L., Bergtold A., Freeman S., Tovey M., Musser J.M., et al. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha/beta. Proc Natl Acad Sci U S A 2001, 98:5752-5757.
138. Manca C., Tsenova L., Freeman S., Barczak A.K., Tovey M., Murray P.J., et al. tuberculosis W/Beijing strains upregulate type I IFNs and increase expression of negative regulators of the Jak-Stat pathway. J Interferon Cytokine Res 2005, 25:694-701.
139. Antonelli L.R., Gigliotti Rothfuchs A., Goncalves R., Roffe E., Cheever A.W., Bafica A., et al. Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. J Clin Invest 2010, 120:1674-1682.
140. Chang E.Y., Guo B., Doyle S.E., Cheng G. Cutting edge: involvement of the type I IFN production and signaling pathway in lipopolysaccharide-induced IL-10 production. J Immunol 2007, 178:6705-6709.
141. Ordway D., Henao-Tamayo M., Harton M., Palanisamy G., Troudt J., Shanley C., et al. The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation. J Immunol 2007, 179:522-531.
142. Rayamajhi M., Humann J., Penheiter K., Andreasen K., Lenz L.L. Induction of IFN-alphabeta enables Listeria monocytogenes to suppress macrophage activation by IFN-gamma. J Exp Med 2010, 207:327-337.
143. Berry M.P., Graham C.M., McNab F.W., Xu Z., Bloch S.A., Oni T., et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010, 466:973-977.
144. Behr M.A. BCG-different strains, different vaccines?. Lancet Infect Dis 2002, 2:86-92.
145. W.H.O.BCG vaccine WHO position paper. Wkly Epidemiol Rec 2004, 79:27-38.
146. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994, 271:698-702.
147. Behr M.A., Wilson M.A., Gill W.P., Salamon H., Schoolnik G.K., Rane S., et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999, 284:1520-1523.
148. Gordon S.V., Brosch R., Billault A., Garnier T., Eiglmeier K., Cole S.T. Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays. Mol Microbiol 1999, 32:643-655.
149. Mahairas G.G., Sabo P.J., Hickey M.J., Singh D.C., Stover C.K. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol 1996, 178:1274-1282.
150. Hsu T., Hingley-Wilson S.M., Chen B., Chen M., Dai A.Z., Morin P.M., et al. The primary mechanism of attenuation of bacillus Calmette-Guerin is a loss of secreted lytic function required for invasion of lung interstitial tissue. Proc Natl Acad Sci U S A 2003, 100:12420-12425.
151. Junqueira-Kipnis A.P., Basaraba R.J., Gruppo V., Palanisamy G., Turner O.C., Hsu T., et al. Mycobacteria lacking the RD1 region do not induce necrosis in the lungs of mice lacking interferon-gamma. Immunology 2006, 119:224-231.
152. Majlessi L., Brodin P., Brosch R., Rojas M.J., Khun H., Huerre M., et al. Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. J Immunol 2005, 174:3570-3579.
153. Houben D., Demangel C., van Ingen J., Perez J., Baldeon L., Abdallah A.M., et al. ESX-1-mediated translocation to the cytosol controls virulence of mycobacteria. Cell Microbiol 2012.
154. van der Wel N., Hava D., Houben D., Fluitsma D., van Zon M., Pierson J., et al. M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell 2007, 129:1287-1298.
155. Stanley S.A., Johndrow J.E., Manzanillo P., Cox J.S. The Type I IFN response to infection with Mycobacterium tuberculosis requires ESX-1-mediated secretion and contributes to pathogenesis. J Immunol 2007, 178:3143-3152.
156. Manzanillo P.S., Shiloh M.U., Portnoy D.A., Cox J.S. Mycobacterium tuberculosis activates the DNA-dependent cytosolic surveillance pathway within macrophages. Cell Host Microbe 2012, 11:469-480.
157. Pym A.S., Brodin P., Majlessi L., Brosch R., Demangel C., Williams A., et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 2003, 9:533-539.
158. Black G.F., Dockrell H.M., Crampin A.C., Floyd S., Weir R.E., Bliss L., et al. Patterns and implications of naturally acquired immune responses to environmental and tuberculous mycobacterial antigens in northern Malawi. J Infect Dis 2001, 184:322-329.
159. Daugelat S., Ladel C.H., Kaufmann S.H. Influence of mouse strain and vaccine viability on T-cell responses induced by Mycobacterium bovis bacillus Calmette-Guerin. Infect Immun 1995, 63:2033-2040.
160. Orme I.M. Induction of nonspecific acquired resistance and delayed-type hypersensitivity, but not specific acquired resistance in mice inoculated with killed mycobacterial vaccines. Infect Immun 1988, 56:3310-3312.
161. Olsen A.W., Brandt L., Agger E.M., van Pinxteren L.A., Andersen P. The influence of remaining live BCG organisms in vaccinated mice on the maintenance of immunity to tuberculosis. Scand J Immunol 2004, 60:273-277.
162. Brandt L., Feino Cunha J., Weinreich Olsen A., Chilima B., Hirsch P., Appelberg R., et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 2002, 70:672-678.
163. Lalor M.K., Floyd S., Gorak-Stolinska P., Ben-Smith A., Weir R.E., Smith S.G., et al. BCG vaccination induces different cytokine profiles following infant BCG vaccination in the UK and Malawi. J Infect Dis 2011, 204:1075-1085.
164. Lalor M.K., Smith S.G., Floyd S., Gorak-Stolinska P., Weir R.E., Blitz R., et al. Complex cytokine profiles induced by BCG vaccination in UK infants. Vaccine 2009.
165. Soares A.P., Scriba T.J., Joseph S., Harbacheuski R., Murray R.A., Gelderbloem S.J., et al. Bacillus Calmette-Guerin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J Immunol 2008, 180:3569-3577.
166. Weir R.E., Black G.F., Nazareth B., Floyd S., Stenson S., Stanley C., et al. The influence of previous exposure to environmental mycobacteria on the interferon-gamma response to bacille Calmette-Guerin vaccination in southern England and northern Malawi. Clin Exp Immunol 2006, 146:390-399.
167. Lalor M.K., Ben-Smith A., Gorak-Stolinska P., Weir R.E., Floyd S., Blitz R., et al. Population differences in immune responses to Bacille Calmette-Guerin vaccination in infancy. J Infect Dis 2009, 199:795-800.
168. Sterne J.A., Rodrigues L.C., Guedes I.N. Does the efficacy of BCG decline with time since vaccination?. Int J Tuberc Lung Dis 1998, 2:200-207.
169. Aronson N.E., Santosham M., Comstock G.W., Howard R.S., Moulton L.H., Rhoades E.R., et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60-year follow-up study. JAMA 2004, 291:2086-2091.
170. Rodrigues L.C., Pereira S.M., Cunha S.S., Genser B., Ichihara M.Y., de Brito S.C., et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 2005, 366:1290-1295.
171. Wakeham J., Wang J., Xing Z. Genetically determined disparate innate and adaptive cell-mediated immune responses to pulmonary Mycobacterium bovis BCG infection in C57BL/6 and BALB/c mice. Infect Immun 2000, 68:6946-6953.
172. Armbruster C., Junker W., Vetter N., Jaksch G. Disseminated bacille Calmette-Guerin infection in an AIDS patient 30 years after BCG vaccination. J Infect Dis 1990, 162:1216.
173. Reynes J., Perez C., Lamaury I., Janbon F., Bertrand A. Bacille Calmette-Guerin adenitis 30 years after immunization in a patient with AIDS. J Infect Dis 1989, 160:727.
174. Talbot E.A., Perkins M.D., Silva S.F., Frothingham R. Disseminated bacille Calmette-Guerin disease after vaccination: case report and review. Clin Infect Dis 1997, 24:1139-1146.
175. Horwitz M.A., Harth G., Dillon B.J., Maslesa-Galic S. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci U S A 2000, 97:13853-13858.
176. Grode L., Seiler P., Baumann S., Hess J., Brinkmann V., Nasser Eddine A., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 2005, 115:2472-2479.
177. Aagaard C., Hoang T., Dietrich J., Cardona P.J., Izzo A., Dolganov G., et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 2011, 17:189-194.
178. Hoft D.F., Blazevic A., Abate G., Hanekom W.A., Kaplan G., Soler J.H., et al. A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis 2008, 198:1491-1501.
179. Schaible U.E., Winau F., Sieling P.A., Fischer K., Collins H.L., Hagens K., et al. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat Med 2003, 9:1039-1046.
180. Winau F., Kaufmann S.H., Schaible U.E. Apoptosis paves the detour path for CD8 T cell activation against intracellular bacteria. Cell Microbiol 2004, 6:599-607.
181. Winau F., Weber S., Sad S., de Diego J., Hoops S.L., Breiden B., et al. Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity 2006, 24:105-117.
182. Vakzine Projekt Management GmbH Study to evaluate safety and immunogenicity of VPM1002 in comparison with BCG in newborn infants in South Africa. ClinicalTrials.gov [Internet] 2000, Bethesda (MD): National Library of Medicine (US), [cited 2012 Oct 23]. Available from:, [NLM Identifier: NCT01479972]. http://clinicaltrials.gov/show/NCT01479972.
183. Asensio J.A., Arbues A., Perez E., Gicquel B., Martin C. Live tuberculosis vaccines based on phoP mutants: a step towards clinical trials. Expert Opin Biol Ther 2008, 8:201-211.
184. Kaufmann S.H. Tuberculosis vaccine development: strength lies in tenacity. Trends Immunol 2012, 33:373-379.
185. Sweeney K.A., Dao D.N., Goldberg M.F., Hsu T., Venkataswamy M.M., Henao-Tamayo M., et al. A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat Med 2011, 17:1261-1268.
186. Williams A., Goonetilleke N.P., McShane H., Clark S.O., Hatch G., Gilbert S.C., et al. Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs. Infect Immun 2005, 73:3814-3816.
187. McShane H., Brookes R., Gilbert S.C., Hill A.V. Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 2001, 69:681-686.
188. Verreck F.A., Vervenne R.A., Kondova I., van Kralingen K.W., Remarque E.J., Braskamp G., et al. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS One 2009, 4:e5264.
189. McShane H., Pathan A.A., Sander C.R., Keating S.M., Gilbert S.C., Huygen K., et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004, 10:1240-1244.
190. Sander C.R., Pathan A.A., Beveridge N.E., Poulton I., Minassian A., Alder N., et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Am J Respir Crit Care Med 2009, 179:724-733.
191. Scriba T.J., Tameris M., Smit E., van der Merwe L., Hughes E.J., Kadira B., et al. A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults. Am J Respir Crit Care Med 2012, 185:769-778.
192. Beveridge N.E., Price D.A., Casazza J.P., Pathan A.A., Sander C.R., Asher T.E., et al. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol 2007, 37:3089-3100.
193. Radosevic K., Wieland C.W., Rodriguez A., Weverling G.J., Mintardjo R., Gillissen G., et al. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect Immun 2007, 75:4105-4115.
194. Rowland R., McShane H. Tuberculosis vaccines in clinical trials. Expert Rev Vaccines 2011, 10:645-658.
195. Wang J., Thorson L., Stokes R.W., Santosuosso M., Huygen K., Zganiacz A., et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 2004, 173:6357-6365.
196. Hoft D.F., Blazevic A., Stanley J., Landry B., Sizemore D., Kpamegan E., et al. A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity. Vaccine 2012, 30:2098-2108.
197. Abel B., Tameris M., Mansoor N., Gelderbloem S., Hughes J., Abrahams D., et al. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir Crit Care Med 2010, 181:1407-1417.
198. Santosuosso M., McCormick S., Zhang X., Zganiacz A., Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun 2006, 74:4634-4643.
199. Lasaro M.O., Ertl H.C. New insights on adenovirus as vaccine vectors. Mol Ther 2009, 17:1333-1339.
200. Tatsis N., Ertl H.C. Adenoviruses as vaccine vectors. Mol Ther 2004, 10:616-629.
201. Brandt L., Skeiky Y.A., Alderson M.R., Lobet Y., Dalemans W., Turner O.C., et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun 2004, 72:6622-6632.
202. Leroux-Roels I., Forgus S., De Boever F., Clement F., Demoitie M.A., Mettens P., et al. Improved CD4 (+) T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine 2012.
203. Leroux-Roels I., Leroux-Roels G., Ofori-Anyinam O., Moris P., De Kock E., Clement F., et al. Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults. Clin Vaccine Immunol 2010, 17:1763-1771.
204. Dietrich J., Andersen C., Rappuoli R., Doherty T.M., Jensen C.G., Andersen P. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. J Immunol 2006, 177:6353-6360.
205. Dietrich J., Aagaard C., Leah R., Olsen A.W., Stryhn A., Doherty T.M., et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 2005, 174:6332-6339.
206. Bertholet S., Ireton G.C., Ordway D.J., Windish H.P., Pine S.O., Kahn M., et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med 2010, 2:53ra74.
207. McShane H., Williams A. Tuberculosis vaccine promises sterilizing immunity. Nat Med 2011, 17:1185-1186.
208. Patel N., Deshpande M.M., Shah M. Effect of an immunomodulator containing Mycobacterium w on sputum conversion in pulmonary tuberculosis. J Indian Med Assoc 2002, 100:191-193.
209. Patel N., Trapathi S.B. Improved cure rates in pulmonary tuberculosis category II (retreatment) with mycobacterium w. J Indian Med Assoc 2003, 101:680-682.
210. Mwinga A., Nunn A., Ngwira B., Chintu C., Warndorff D., Fine P., et al. Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial. Lancet 2002, 360:1050-1055.
211. Mayo R.E., Stanford J.L. Double-blind placebo-controlled trial of Mycobacterium vaccae immunotherapy for tuberculosis in KwaZulu, South Africa, 1991-97. Trans R Soc Trop Med Hyg 2000, 94:563-568.
212. Vuola J.M., Ristola M.A., Cole B., Jarviluoma A., Tvaroha S., Ronkko T., et al. Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial. AIDS 2003, 17:2351-2355.
213. Lahey T., Arbeit R.D., Bakari M., Horsburgh C.R., Matee M., Waddell R., et al. Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania. Vaccine 2010, 28:7652-7658.
214. von Reyn C.F., Mtei L., Arbeit R.D., Waddell R., Cole B., Mackenzie T., et al. Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010, 24:675-685.
215. Kagina B.M., Abel B., Scriba T.J., Hughes E.J., Keyser A., Soares A., et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am J Respir Crit Care Med 2010, 182:1073-1079.
216. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007, 13:843-850.
217. Mittrucker H.W., Steinhoff U., Kohler A., Krause M., Lazar D., Mex P., et al. Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis. Proc Natl Acad Sci U S A 2007, 104:12434-12439.
218. Majlessi L., Simsova M., Jarvis Z., Brodin P., Rojas M.J., Bauche C., et al. An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis. Infect Immun 2006, 74:2128-2137.
219. Kagina B.M., Abel B., Bowmaker M., Scriba T.J., Gelderbloem S., Smit E., et al. Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell response. Vaccine 2009, 27:5488-5495.
220. Henao-Tamayo M.I., Ordway D.J., Irwin S.M., Shang S., Shanley C., Orme I.M. Phenotypic definition of effector and memory T-lymphocyte subsets in mice chronically infected with Mycobacterium tuberculosis. Clin Vaccine Immunol 2010, 17:618-625.
221. Chackerian A.A., Alt J.M., Perera T.V., Dascher C.C., Behar S.M. Dissemination of Mycobacterium tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity. Infect Immun 2002, 70:4501-4509.
222. Reiley W.W., Calayag M.D., Wittmer S.T., Huntington J.L., Pearl J.E., Fountain J.J., et al. ESAT-6-specific CD4 T cell responses to aerosol Mycobacterium tuberculosis infection are initiated in the mediastinal lymph nodes. Proc Natl Acad Sci U S A 2008, 105:10961-10966.
223. Wolf A.J., Desvignes L., Linas B., Banaiee N., Tamura T., Takatsu K., et al. Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J Exp Med 2008, 205:105-115.
224. Winslow G.M., Cooper A., Reiley W., Chatterjee M., Woodland D.L. Early T-cell responses in tuberculosis immunity. Immunol Rev 2008, 225:284-299.
225. Urdahl K.B., Shafiani S., Ernst J.D. Initiation and regulation of T-cell responses in tuberculosis. Mucosal Immunol 2011, 4:288-293.
226. Goonetilleke N.P., McShane H., Hannan C.M., Anderson R.J., Brookes R.H., Hill A.V. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 2003, 171:1602-1609.
227. Palendira U., Bean A.G., Feng C.G., Britton W.J. Lymphocyte recruitment and protective efficacy against pulmonary mycobacterial infection are independent of the route of prior Mycobacterium bovis BCG immunization. Infect Immun 2002, 70:1410-1416.
228. Gheorghiu M. BCG-induced mucosal immune responses. Int J Immunopharmacol 1994, 16:435-444.
229. Nuermberger E.L., Yoshimatsu T., Tyagi S., Bishai W.R., Grosset J.H. Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG. Infect Immun 2004, 72:1065-1071.
230. Ronan E.O., Lee L.N., Beverley P.C., Tchilian E.Z. Immunization of mice with a recombinant adenovirus vaccine inhibits the early growth of Mycobacterium tuberculosis after infection. PLoS One 2009, 4:e8235.
231. Santosuosso M., McCormick S., Roediger E., Zhang X., Zganiacz A., Lichty B.D., et al. Mucosal luminal manipulation of T cell geography switches on protective efficacy by otherwise ineffective parenteral genetic immunization. J Immunol 2007, 178:2387-2395.
232. O'Garra A., Barrat F.J., Castro A.G., Vicari A., Hawrylowicz C. Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev 2008, 223:114-131.
233. Castro A.G., Neighbors M., Hurst S.D., Zonin F., Silva R.A., Murphy E., et al. Anti-interleukin 10 receptor monoclonal antibody is an adjuvant for T helper cell type 1 responses to soluble antigen only in the presence of lipopolysaccharide. J Exp Med 2000, 192:1529-1534.
234. Roberts M.T., Stober C.B., McKenzie A.N., Blackwell J.M. Interleukin-4 (IL-4) and IL-10 collude in vaccine failure for novel exacerbatory antigens in murine Leishmania major infection. Infect Immun 2005, 73:7620-7628.
235. Stober C.B., Lange U.G., Roberts M.T., Alcami A., Blackwell J.M. IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection. J Immunol 2005, 175:2517-2524.
236. Tabbara K.S., Peters N.C., Afrin F., Mendez S., Bertholet S., Belkaid Y., et al. Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection. Infect Immun 2005, 73:4714-4722.
237. Darrah P.A., Hegde S.T., Patel D.T., Lindsay R.W., Chen L., Roederer M., et al. IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform. J Exp Med 2010, 207:1421-1433.
238. Brooks D.G., Lee A.M., Elsaesser H., McGavern D.B., Oldstone M.B. IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection. J Exp Med 2008, 205:533-541.
239. Pitt J.M., Stavropoulos E., Redford P.S., Beebe A.M., Bancroft G.J., Young D.B., et al. Blockade of IL-10 signaling during bacillus calmette-guerin vaccination enhances and sustains Th1, Th17, and innate lymphoid IFN-gamma and IL-17 responses and increases protection to mycobacterium tuberculosis infection. J Immunol 2012, 189:4079-4087.
240. Murray P.J., Aldovini A., Young R.A. Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guerin strains that secrete cytokines. Proc Natl Acad Sci U S A 1996, 93:934-939.
241. Ryan A.A., Wozniak T.M., Shklovskaya E., O'Donnell M.A., Fazekas de St Groth B., Britton W.J., et al Improved protection against disseminated tuberculosis by Mycobacterium bovis bacillus Calmette-Guerin secreting murine GM-CSF is associated with expansion and activation of APCs. J Immunol 2007, 179:8418-8424.
242. Ada G. Vaccines and vaccination. N Engl J Med 2001, 345:1042-1053.
243. Rosenthal K.S., Zimmerman D.H. Vaccines: all things considered. Clin Vaccine Immunol 2006, 13:821-829.
244. Vilaplana C., Montane E., Pinto S., Barriocanal A.M., Domenech G., Torres F., et al. Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI. Vaccine 2010, 28:1106-1116.